DYSF and neuromuscular disease caused by qualitative or quantitative defects of dysferlin: In myocytes developed from induced pluripotent stem cells from a patient carrying p.Trp999Cys mutation, nocodazole treatment increases dysferlin levels and improves membrane resealing, suggesting that dysferlin degradation may be a potential drug target for the treatment of dysferlinopathy (Kokubu et al., 2019).